Downstream Treatment Burden and Health‐Care Utilization Following Initiation of <scp>GLP</scp> ‐1 Receptor Agonists or <scp>SGLT2</scp> Inhibitors in Type 2 Diabetes

Initiation of GLP-1 receptor agonists is associated with a downstream pharmacologic cascade characterized by increased use of symptom-driven medication without corresponding increases in health-care utilization. Medication initiation may provide a more sensitive measure of treatment burden than diagnostic codes or utilization metrics in routine diabetes care. To our knowledge, this study represents the largest multicentre real-world evaluation of downstream pharmacologic cascades following initiation of GLP-1 receptor agonists and SGLT2 inhibitors.